Similarly, RAS-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines, and activated ERK has been implicated in doxorubicin-mediated cell death, independent of p53 status [20,21]. Here, MAPK1 is linked to neuroblastoma.